FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.
What happened
FDA inspected Dr. Cole's clinical site from May 12 to 16, 2025, as part of its program to check research conduct. FDA found that all four enrolled subjects received 10 mg of the study drug at multiple visits, even though their assigned maximum weekly doses were 1.5, 4.5, or 9.0 mg. The subjects had nausea, vomiting, stomach pain, fatigue, dizziness, heartburn, and injection-site reactions while receiving the wrong doses.
What FDA found
Dr. Cole did not ensure the study was run according to the investigational plan (the study's required procedures).
21 CFR 312.60All four enrolled subjects received 10 mg of study drug at multiple visits, above their assigned maximum weekly target doses.
21 CFR 312.60Subjects had multiple adverse events while receiving the incorrect doses.
21 CFR 312.60Site staff who gave the study drug were not originally delegated and trained for that task, according to the company's response.
The company's response lacked enough detail on training, procedures, and investigator oversight to prevent repeat violations.
What FDA wants
Within 15 business days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations. Include details on training, procedures, and how the investigator will oversee study procedures.
Who should pay attention
- clinical trial sponsors
- contract research organizations
- clinical investigators and site staff
This is a summary. Read the original letter on fda.gov.